| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | 0.19 | 0.0001 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | 0.2 | 0.0001 |
| mRNA | Vinblastine | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.19 | 0.0005 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0005 |
| mRNA | Parthenolide | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0006 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0006 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.17 | 0.002 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |